Pharma Exclusives Pressreleases
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Friday, September 26, 2025CSL Vifor and Travere Therapeutics Inc support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy IgAN Kidney Disease Improving Global Outcomes KDIGO clinical practice guideline for the management...
Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
Monday, September 22, 2025AstraZeneca and Amgens Tezspire tezepelumab has been recommended for approval in the European Union EU for the treatment of adult patients with chronic rhinosinusitis with nasal polyps CRSwNP
ToxTracker® Approved by OECD for Incorporation into Test Guideline Programme
Thursday, September 04, 2025Toxys a leading innovator in animalfree toxicology solutions announces that its flagship product ToxTracker has been accepted into the Organization for Economic Cooperation and Development OECD
CrystalsFirst to Exclusively Offer NexMRʼs Ultrafast NMR Screening Technology for Fragment-Based Drug Discovery
Thursday, September 04, 2025CrystalsFirst GmbH a leader in highperformance structural biology services and NexMR AG a pioneer in ultrafast NMR screening today announced an exclusive partnership to accelerate fragmentbased drug discovery
Quotient Sciences and CPI to Accelerate RNA Drug Development with Joint Venture
Wednesday, September 03, 2025Quotient Sciences a leading global drug development and manufacturing accelerator and UK technology innovation centre CPI have signed a memorandum of understanding MoU to form a Joint Venture
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Monday, September 01, 2025Boehringer Ingelheims HERNEXEOS zongertinib tablets has been approved as monotherapy by Chinas National Medical Products Administration NMPA for the treatment of adult patients with unresectable
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Tuesday, August 26, 2025Gilead Sciences Inctoday announced that the European Commission EC has granted marketing authorization for Yeytuo lenacapavirthe companys twiceyearly injectable HIV capsid inhibitor
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
Monday, August 25, 2025H Lundbeck AS Lundbeck today announced that new data regarding bexicaserin a novel treatment under investigation for seizures associated with Developmental and Epileptic Encephalopathies DEEs
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
Monday, August 25, 2025Eisai Co Ltdand Biogen Inc Nasdaq BIIB Corporate headquarters Cambridge Massachusetts CEO Christopher A Viehbacher Biogen announced today that the antiamyloid beta A monoclonal antibody
BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
Tuesday, August 19, 2025BioMed X an independent biomedical research institute based in Heidelberg Germany announced today the launch of a new collaboration with Novo Nordisk a leading global healthcare company headquartered
